Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Verinurad QTcF study in healthy volunteers
NCT04256629Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of verinurad in chronic kidney disease (CKD) (6 arms), sponsored by AstraZeneca. Primary endpoint: Model Predicted Baseline-corrected and Placebo-corrected QT Interval Corrected for Heart Rate Using Fridericia's Formula at Day 3. Started Mar 2020; status: completed.
02
Drugs
verinurad
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04256629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04256629.